Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer

Bevacizumab is a monoclonal antibody which is a vascular endothelial growth factor inhibitor. It obscures vascularization of tumor tissue and damages intratumoral microcirculation. The damaged intratumoral microcirculation leads to tissue hypoxia and results in increase of uric acid level. The main aim of our study was to investigate the relationship between uric acid change and response to bevacizumab therapy. This study included a total of 158 patients with metastatic colorectal cancer who had received bevacizumab therapy. The number of male patients was 100 (63.3 %) while female patients number was 58 (37.7 %). The median age was 61 (29–83). There was relationship between increase of uric acid level of third month uric acid level and stable disease (p < 0.001). There was a significant overall survival increased in the group with increased uric acid level (p < 0.001). The decline of CEA level was related to uric acid level (p < 0.022). In conclusion, this study is the first showing significant increases of serum uric acid in patients with metastatic colorectal cancer who favorably responded to chemotherapy with bevacizumab. But further studies are justified to test whether monitoring uric acid levels might predict clinical outcomes of patients with metastatic colorectal cancer.     

Periodontal status of patients with reduced immunocapacity.

The periodontal status of patients with reduced immunocapacity was assessed. Gingival inflammation, periodontal destruction, and plaque accumulation were compared in three groups--renal transplant patients, dialysis patients, and normal individuals. The levels of all parameters were similar in the three groups indicating that immunosuppression does not affect the clinical appearance of periodontal disease when measurements are made in a single examination. In the transplant group, however, there is a lack of correlation between P.I. and G.I. and between P.I. and P.D.I., indicating a dissociation between plaque accumulation and the tissue response. Long-term longitudinal studies of periodontal disease in such patients are needed in order to obtain more meaningful information on the role of the immune system in affecting the rate of periodontal destruction. This study suggests that nonimmune mechanisms such as the direct effect of bacterial products on supporting tissues can account for at least some of the clinical manifestations of periodontal disease.     

Primary Sjögren's syndrome

Columbia University's Salivary Gland Center (SGC) has examined more than 6,000 patients with a variety of concerns stemming from salivary gland disease and/or salivary secretory dysfunction. Not unexpectedly, the most common patient complaint centers around symptoms associated with dry mouth. Such patients are usually first seen by the dental practitioner. Because Sj?gren's syndrome (SS) causes dry mouth, and because it is a relatively common entity--encountered in about three million Americans--and because the dental profession has become aware of its classic manifestation of xerostomia, patients experiencing SS are referred in increasing numbers to the SGC for evaluation. Therefore, the authors wish to call attention to the methodology used in accurately diagnosing SS and to illustrate its signs and symptoms with a case report.     

Sjogren's syndrome. Dental role in providing relief.

This oftentimes underappreciated disease carries with it severe dental implications, all of which can affect the patient's quality of life. While there is no cure, it is possible to manage disease symptoms and to prevent irreversible dental damage.     

Cytomegalovirus presence and salivary composition in acquired immunodeficiency syndrome

Parotid and whole saliva was collected from nine patients with acquired immunodeficiency syndrome (AIDS) and nine controls. Cytomegalovirus (CMV) was cultured from both salivary samples in six of the AIDS patients but was not present in any of the controls. In the AIDS samples parotid sodium (p less than 0.05), IgG (p less than 0.01), and albumin (p less than 0.05) were higher than in control samples. Parotid potassium (p less than 0.05) and total protein (p less than 0.05) were lower than control values, whereas flow rate, lactoferrin, lysozyme, IgA, and IgM levels were similar in both sets of samples. AIDS does not appear to affect secretory IgA levels. Sodium (p less than 0.01) and IgA (p less than 0.05) were higher in the whole saliva of AIDS patients. Serum IgG, IgM (p less than 0.01), and IgA (p less than 0.05) were also elevated when compared with the controls. The prevalence of CMV in parotid and whole saliva of AIDS patients is consistent with the known susceptibility of this group to adventitious infection and the predilection of this virus for the salivary glands. The changes in salivary composition suggest a low level of inflammation, which occurs independently of the virus.     

Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis

Background:

We investigated the additional contribution of mammography to screening accuracy in BRCA1/2 mutation carriers screened with MRI at different ages using individual patient data from six high-risk screening trials.

Methods:

Sensitivity and specificity of MRI, mammography and the combination of these tests were compared stratified for BRCA mutation and age using generalised linear mixed models with random effect for studies. Number of screens needed (NSN) for additional mammography-only detected cancer was estimated.

Results:

In BRCA1/2 mutation carriers of all ages (BRCA1=1219 and BRCA2=732), adding mammography to MRI did not significantly increase screening sensitivity (increased by 3.9% in BRCA1 and 12.6% in BRCA2 mutation carriers, P>0.05). However, in women with BRCA2 mutation younger than 40 years, one-third of breast cancers were detected by mammography only. Number of screens needed for mammography to detect one breast cancer not detected by MRI was much higher for BRCA1 compared with BRCA2 mutation carriers at initial and repeat screening.

Conclusions:

Additional screening sensitivity from mammography above that from MRI is limited in BRCA1 mutation carriers, whereas mammography contributes to screening sensitivity in BRCA2 mutation carriers, especially those ⩽40 years. The evidence from our work highlights that a differential screening schedule by BRCA status is worth considering.